Q2 Earnings Forecast for OFIX Issued By Barrington Research

Orthofix Medical Inc. (NASDAQ:OFIX) – Analysts at Barrington Research issued their Q2 2025 earnings estimates for shares of Orthofix Medical in a note issued to investors on Monday, June 23rd. Barrington Research analyst M. Petusky forecasts that the medical device company will post earnings of ($0.72) per share for the quarter. Barrington Research has a “Strong-Buy” rating and a $16.00 price target on the stock. The consensus estimate for Orthofix Medical’s current full-year earnings is ($2.81) per share. Barrington Research also issued estimates for Orthofix Medical’s Q3 2025 earnings at ($0.58) EPS, Q4 2025 earnings at ($0.40) EPS, FY2025 earnings at ($3.04) EPS, Q1 2026 earnings at ($0.83) EPS, Q2 2026 earnings at ($0.67) EPS, Q3 2026 earnings at ($0.50) EPS, Q4 2026 earnings at ($0.34) EPS, FY2026 earnings at ($2.34) EPS and FY2027 earnings at ($1.64) EPS.

A number of other research analysts have also recently issued reports on OFIX. JMP Securities reissued a “market perform” rating on shares of Orthofix Medical in a research note on Friday, June 6th. Wall Street Zen upgraded Orthofix Medical from a “sell” rating to a “hold” rating in a research report on Saturday, June 14th. Two analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Orthofix Medical currently has a consensus rating of “Moderate Buy” and a consensus price target of $21.50.

Orthofix Medical Price Performance

OFIX opened at $11.04 on Thursday. The stock has a market cap of $432.55 million, a P/E ratio of -2.99 and a beta of 0.80. Orthofix Medical has a 12 month low of $10.24 and a 12 month high of $20.73. The company has a quick ratio of 1.50, a current ratio of 2.71 and a debt-to-equity ratio of 0.38. The company has a fifty day simple moving average of $11.89 and a 200 day simple moving average of $15.29.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in OFIX. Rhumbline Advisers boosted its stake in shares of Orthofix Medical by 1.2% during the 4th quarter. Rhumbline Advisers now owns 54,989 shares of the medical device company’s stock worth $960,000 after buying an additional 661 shares during the last quarter. Invesco Ltd. raised its holdings in Orthofix Medical by 1.0% during the fourth quarter. Invesco Ltd. now owns 74,977 shares of the medical device company’s stock worth $1,309,000 after acquiring an additional 767 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Orthofix Medical by 4.5% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,348 shares of the medical device company’s stock valued at $338,000 after purchasing an additional 836 shares during the last quarter. Gamco Investors INC. ET AL grew its stake in Orthofix Medical by 1.0% in the first quarter. Gamco Investors INC. ET AL now owns 157,100 shares of the medical device company’s stock valued at $2,562,000 after purchasing an additional 1,500 shares in the last quarter. Finally, Swiss National Bank grew its stake in Orthofix Medical by 2.6% in the fourth quarter. Swiss National Bank now owns 67,600 shares of the medical device company’s stock valued at $1,180,000 after purchasing an additional 1,700 shares in the last quarter. Institutional investors own 89.76% of the company’s stock.

Insider Buying and Selling

In other Orthofix Medical news, insider Aviva Mcpherron sold 3,728 shares of the business’s stock in a transaction that occurred on Wednesday, June 18th. The stock was sold at an average price of $10.51, for a total value of $39,181.28. Following the sale, the insider now owns 46,322 shares in the company, valued at approximately $486,844.22. The trade was a 7.45% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Engine Capital Management, Lp purchased 100,000 shares of the firm’s stock in a transaction dated Wednesday, May 7th. The shares were acquired at an average cost of $12.31 per share, with a total value of $1,231,000.00. Following the completion of the purchase, the insider now directly owns 3,544,807 shares in the company, valued at approximately $43,636,574.17. This represents a 2.90% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 112,250 shares of company stock valued at $1,380,970 and sold 7,620 shares valued at $91,168. Company insiders own 1.30% of the company’s stock.

Orthofix Medical Company Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.